Showing results (21-30 of 76) with videos related to
Sort By:
Pageof 8
Anticancer Research|July 2, 2014
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impactMaria Vittoria Dieci, Federico Piacentini, Massimo Dominici, et al.Genes|March 29, 2023
Personalized Systemic Therapies in Hereditary Cancer SyndromesLuciana Mastrodomenico, Claudia Piombino, Beatrice Riccò, et al.The International Journal of Biological Markers|June 15, 2010
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysisValentina Guarneri, Elena Barbieri, Federico Piacentini, et al.Annals of Surgical Oncology|January 10, 2015
Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be studyValentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, et al.Translational Oncology|June 3, 2020
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant ChemotherapyClaudia Omarini, Stefania Bettelli, Samantha Manfredini, et al.BMC Cancer|May 15, 2020
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trialsClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.Breast Cancer (Tokyo, Japan)|December 20, 2018
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapyGiorgia Guaitoli, Federico Piacentini, Claudia Omarini, et al.Journal of Clinical Pathology|March 6, 2012
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysisMaria Vittoria Dieci, Elena Barbieri, Stefania Bettelli, et al.Biomedicines|January 21, 2023
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesKrisida Cerma, Federico Piacentini, Luca Moscetti, et al.Clinical Breast Cancer|September 29, 2023
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-AnalysisRaffaella D'Onofrio, Isabella Sperduti, Federico Piacentini, et al.Pageof 8